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Abstract
Background: Cholangiocarcinoma (CCA) is an aggressive disease with poor prognosis. A molecular classification
based on mutational, methylation and transcriptomic features could allow identifying tailored therapies to improve
CCA patient outcome. Proteomic remains partially unexplored; here, we analyzed the proteomic profile of five
intrahepatic cholangiocarcinoma (ICC) derived from Italian patients undergone surgery and one normal bile duct
cell line.
Methods: Proteome profile was investigated by using 2D electrophoresis followed by Mass Spectrometry (MS). To
validate proteomic data, the expression of four overexpressed proteins (CAT, SOD, PRDX6, DBI/ACBP) was evaluated
by immunohistochemistry in an independent cohort of formalin fixed, paraffin-embedded (FFPE) ICC tissues. We
also compared proteomic data with those obtained by transcriptomic profile evaluated by microarray analysis of
the same tissues.
Results: We identified 19 differentially expressed protein spots, which were further characterized by MS; 13 of them
were up- and 6 were down-regulated in ICC. These proteins are mainly involved in redox processes (CAT, SODM,
PRDX2, PRDX6), in metabolism (ACBP, ACY1, UCRI, FTCD, HCMS2), and cell structure and organization (TUB2, ACTB).
CAT is overexpressed in 86% of patients, PRDX6 in 73%, SODM in 100%, and DBI/ACBP in 81% compared to normal
adjacent tissues. A concordance of 50% between proteomic and transcriptomic data was observed.
Conclusions: This study pointed out that the impairment of the metabolic and antioxidant systems, with a
subsequent accumulation of free radicals, might be a key step in CCA development and progression.
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Background
Cholangiocarcinoma (CCA) is the second most common
type of hepatobiliary cancer arising from the ductal epi-
thelium of the biliary tree, either within the liver (intra-
hepatic cholangiocarcinoma, ICC) or from extrahepatic
bile ducts (extrahepatic cholangiocarcinoma, ECC),
which included perihilar and distal cholangiocarcinoma
[1]. CCA incidence, pathogenesis and etiology differ not
only among the subtypes, but also according to ethnicity,
with peculiar genetic alterations and risk factors [2].
Globally, its incidence is higher in Asiatic Countries of
the Pacific area, especially due to parasite infection, but
the number of cases in Europe is increasing in the last
30 years [3]. As it concerns Italy, a retrospective study
demonstrated that CCA incidence in the years 1988–
2005 displayed an annual increment of 3–6%, with
highly increased rate and mortality for ICC compared to
ECC [4]. A minority of patients had surgically resectable
tumors at diagnosis, but the recurrence rate was higher
than 50% within 5 years, since the diagnosis was often
delayed [5]. The therapeutic approach for locally ad-
vanced or metastatic diseases is chemotherapy; the back-
bone is represented by Gemcitabine in association with
platinum compounds, with a median overall survival of
11.7 months compared to 8.1 months of gemcitabine
alone [6]. Unfortunately, patients developed resistance
and disease progression occurred, making this path-
ology highly lethal. The molecular mechanisms and gen-
etic steps underlying the pathogenesis of this tumor
remain largely unknown; the heterogeneity of these
tumors, the different etiology and risk factors involved
in tumor development, complicate the identification
of suitable molecular target and treatment options. In
the last years, the importance to properly classify
CCA emerged, considering the subtypes as different
entities. Large-scale technologies, such as whole gen-
ome sequencing, RNA-seq, microarray and methyla-
tion arrays, highlighted the real need to distinguish
either the subtypes or the intra- and inter-tumoral
heterogeneity of CCA [7–9]. It is well-known that
some mutations such as IDH1, BAP1, ARID1A, and
FGFR2 rearrangements are typically enriched in ICC,
while KRAS and TP53 in ECC [10]. In general, IDH1
and FGFR2 aberrations are associated with better
prognosis, while KRAS and TP53 with worse outcome
[11, 12]. These data enforced the real need to treat
ICC and ECC with tailored clinical approaches. In-
deed, not only mutations, but also distinct patterns of
epigenetic alteration profiling may differentiate ICC
from ECC [13]. Moreover, recent studies demon-
strated that a classification based on etiology and mo-
lecular aspects, such as methylation and copy number
variations, is complementary and more useful than
the subtypes classification alone [14].
Although there are lots of information about transcrip-
tomic and mutational status, the proteomic profile of
CCA remains only partially explored and is mainly asso-
ciated to particular histotypes and/or ethnic origin, in
turn strictly associated with risk factors.
In a study of Dos Santos and coll. a panel of 39 altered
proteins involved in motility and actin cytoskeleton re-
modeling was found in an ICC case series compared to
non-tumoral adjacent liver tissue [15]. In an Asiatic case
series, Annexin A2, peroxiredoxin 1 and, ezrin-radixin-
moesin–binding phosphoprotein 50 were identified as
negative prognostic markers of CCA patients [16, 17].
Kristiansen and coll analyzed a case series of CCA, identi-
fying some deregulated proteins, some of them never been
associated with CCA arising and progression [18].
A recent review summarized the uniqueness molecular
profile of liver fluke-associated CCA obtained by combin-
ing multi-omics approaches. Anti-inflammatory, immuno-
modulator/immunosuppressor, epidermal growth factor
receptor or platelet-derived growth factor receptor inhibi-
tors, multi-targeted tyrosine kinase inhibitor, IL6 antagon-
ist, Nuclear Factor-κB inhibitor, histone modulator,
proteasome inhibitor MetAP2 inhibitor, 1,25(OH)2D3 and
cyclosporine A are suggested as targets for the treatment
of this tumor subtype [19].
Recently, the comparison of 6 tumor and peritumoral
ECC tissues identified 233 de-regulated proteins, one of
them, the up-regulated PPP3CA, is a strong predictor of
poor survival [20].
To date, no proteome profiling has been explored in
CCA derived from Italian patients. Here, we selected a
homogeneous series of five ICC tumors obtained at the
time of surgery. We processed them with 2-dimensional
(2D) electrophoresis followed by mass spectrometry. The
comparison of the proteomic profile with that obtained
from a normal epithelial bile duct cell line provided pre-
cious information about the pathways potentially involved
in tumor development and progression.
Methods
Cell line and tumor samples
Normal biliary epithelium cell line HIBEpiC (ScienCell
Research Laboratories, Carlsbad, CA) was cultured in
RPMI 1640 (Gibco, Carlsbad, CA, USA) medium supple-
mented with 10% fetal bovine serum (Sigma–Aldrich, St.
Louis,MO, USA) and 1% penicillin/streptomycin (Life
Technologies Gathersburg, MD) at 37 °C and 5% CO2.
Tumor samples, 5 ICC fresh frozen (FF) tissues and 15
ICC formalin fixed, paraffin embedded (FFPE), were col-
lected from ICC patients of Italian origin. Among FF
ICC samples, 3 derived from females, 2 from males, with
a median age at the time of diagnosis of 69 years. Tumor
tissues used for the experiments were macrodissected
from surgical samples, avoiding the inner (more
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necrotic) and the peripheral part of tumors (useful for
margins evaluation in diagnosis). Biological material was
obtained after informed consent, following institutional
review board-approved protocols (001-IRCC-00IIS-10
FPO-IRCCS, Istituto di Ricovero e Cura a Carattere
Scientifico Candiolo (TO), Italy).
Proteomic analysis by 2 dimensional (2D) electrophoresis
and mass spectrometry
Five ICC and one normal epithelial bile duct cell line
were subjected to proteomic analysis. Cells in culture
were harvested and centrifuged at 400 g for 10 min at
room temperature and washed once in 0.3 M sucrose.
The pellet was collected and treated with 100 μl/1 × 106
cells of lysis buffer (7M Urea, 2M Thiourea, 4% CHAP
S, 1 mM EDTA, 2mM PMSF, 1 mM NaF, 40 mM Tris,
pH 9) containing protease inhibitors (Halt Protease,
Thermo Fisher Scientific, Cat. No. 78429). After vortex-
ing 3 times for 10 s, the cells were sonicated at 20 kHz
and 4 °C for pulses of 20 s with 20 s rest, for a total pro-
cessing time of 3 min. The suspension was incubated for
30 min on a rotating wheel and then centrifuged 30 min
at 13000 xg and 4 °C to remove particulate material. The
supernatant was collected, placed in a clean microcentri-
fuge tube and centrifuged again 15 min at 13000 xg and
4 °C. At the end of the procedure, the supernatant was
collected in a clean microcentrifuge tube and total pro-
tein content was determined with the Bradford assay.
For tissue samples, the procedure was slightly differ-
ent. Samples were washed twice with sterile normal sa-
line (0.15M NaCl) under a laminar flow hood to remove
contaminating hemoglobin and minced with a sterile
scalpel. The small pieces were then transferred in a tube
together with lysis buffer plus protease inhibitors in a
weight (g) to volume (ml) ratio of 1:3. The samples were
then subjected to homogenization by using a Polytron
Homogenizer with brief cycles and on ice bath. At the
end of the procedure, samples were transferred in clean
microcentrifuge tubes and centrifuged for 30 min at
13000 xg and 4 °C. The supernatants were collected and
subjected to another centrifugation at 15 min at 13000
xg and 4 °C. Finally, supernatants were collected and
assayed for total protein content with the Bradford
assay.
All samples were processed separately and subjected
to 2D electrophoresis as follow. Tree hundreds μg of
proteins were subjected to isoelectric focusing (IEF) and
separated on 2D SDS-PAGE on 12.5% polyacrylamide
gels as described by Carcoforo and collaborators [21].
Gels were stained with colloidal Coomassie, and scanned
with the Molecular Imager PharosFX System. The ana-
lysis was then performed using the ProteomWeaver 4
program (Bio-Rad, Hercules, CA, USA). Protein spots
were automatically identified and manually adjusted if
needed, then merged by Pair Matching or Multi Match-
ing function in the software. Each spot was normalized
by the total density of the gel to account for possible dif-
ferences in stain procedure and amount of protein
loaded. Differences in spot intensities between ICC and
control were considered significant if the matched spots
had a fold change > 2 for the upregulated and < 0.5 for
downregulated signals and a p-value < 0.01 in Student’s
t-test. Differentially expressed spots were then processed
for mass spectrometry-based peptide identification.
Briefly, gel fragments were washed in 100 mM ammo-
nium bicarbonate and 50% (v/v) ACN, dehydrated by in-
cubation in 100% (v/v) ACN and rehydrated in 50mM
ammonium bicarbonate containing 4 ng/μL of trypsin;
50 mM ammonium bicarbonate was added following di-
gestion overnight at 37 °C. Tryptic peptides were con-
centrated with ZipTip mC18 pipette tips (Millipore) and
co-eluted onto the MALDI target in 1 μL of α-cyano-4-
hydroxycinnamic acid matrix (5 mg/mL in 50% ACN,
0.1% TFA). MALDI-MS and MALDI-MS/MS were car-
ried out with a 5800 MALDI TOF/TOF Analyzer (Sciex,
Ontario—Canada) essentially as described by Carcoforo
and collaborators [21] and detailed in supplementary
methods (Additional file 1).
Immunohistochemistry
Catalase expression was evaluated in 15 ICC tumors.
Briefly, tumor sections were deparaffinized and rehy-
drated with graded of ethanol. The epitope retrieval was
obtained using Antigen Retrieval Citrate solution pH 6.0
and exposed to 2 min cycles at 700W in a microwave
oven. Endogenous peroxidase activity was blocked with
0.3% hydrogen peroxide for 10 min, followed by treat-
ment with V-block for 30 min (Dako, Santa Clara, CA).
Sections were incubated for 2 h in a moist chamber at
room temperature with the specific primary antibody for
CAT (mouse anti Human CAT, 1:100, Santa Cruz) di-
luted in TBS 1X. Then, slides were rinsed twice in buffer
and then incubated with the detection system solution, a
Dextran polymer conjugated to horseradish peroxidase,
for 30 min. The final reaction was visualized using 3,3′-
diaminobenzidine in a buffer/hydrogen peroxide solu-
tion for 3 min. Finally, sections were counterstained with
Harris’s hematoxylin, dehydrated, and mounted in DPX
(Sigma Aldrich, Saint Louis, MO, USA). Eleven ICC tu-
mors (for five samples, the biological material is not
available and one more tumor tissue was added) were
stained for PRDX6, SODM, and DBI (Aurogene). Briefly,
after rehydration, the endogenous peroxidases were
blocked in a solution of methanol and hydrogen perox-
ides (0.3%) for 30 min. The epitope retrieval was ob-
tained using Antigen Retrieval Citrate solution pH 6.0
(Dako) and exposed to 2 cycles of 5 min each at 850W
in a microwave oven. The saturation of non-specific sites
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was performed with a solution of 5% Normal Goat
Serum (Dako) in TBS-Tween (0.3%)-Triton (0.1%) for 1
h in moist chamber at room temperature. Then, slides
were incubated O/N at 4 °C with the appropriate pri-
mary antibodies at the following dilutions: 1:50 for rabbit
polyclonal PRDX6, 1:200 for mouse monoclonal SODM
and rabbit polyclonal DBI in the saturation solution.
After rinsing, slides were incubated with anti-Rabbit-
HRP (for DBI and PRDX6) and with anti-Mouse-HRP
(for SODM) for 1 h at room temperature. The final reac-
tion was visualized using DAB+ Substrate Chromogen
System (Dako) for 3 min. Finally, sections were counter-
stained with Harris’s hematoxylin, dehydrated, and
mounted in DPX (Sigma Aldrich). Immunohistochemi-
cal results were evaluated by two different pathologists
(LD and GDR). For CAT and ACBP/DBI expression, the
intensity of the reaction was classified using a three
grade system: weak positivity (a weak intensity cytoplas-
matic staining observed in < 30% of the cells), intermedi-
ate positivity (a moderate intensity cytoplasmatic
staining observed in > 30% of the tumor cells), and
strong positivity (a strong intensity cytoplasmatic stain-
ing observed in > 30% of the tumor cells). For SODM
the percentage of positive tumor cells was evaluated on
a scale of 0–3 (0 no staining, 1+ < 10%, 2+ 11–30%, 3+
31–50%, 4+ > 50%). For PRDX6 the staining was scored
as the product of the staining intensity (on a scale of 0–
2: negative = 0, low = 1, high = 2) and the percentage of
cells stained (on a scale of 0–3:0 = zero, 1 = 1–25%, 2 =
26–50%, 3 = 51–100%) resulting in scores on a scale of
0–5.
External dataset for gene expression profiling
We extrapolated the gene expression data of the 5 ICC
tumors used for proteomic analysis from the dataset
GSE107102. They were included in a bigger cohort of
ICC tumors analyzed in our previous work [22]. Material
and methods used are previously deeply described in
Peraldo-Neia et al. [22]. Gene Expression Profiling Inter-
active analysis GEPIA (http://gepia.cancer-pku.cn) data-
base and the Human Protein Atlas (https://www.
proteinatlas.org) database were used to verify the expres-
sion at mRNA and protein levels, respectively, of differ-
entially expressed targets selected by proteomic analysis.
Results
Analysis of differentially expressed proteins
Five tissue samples of ICC patients and normal control
(normal biliary epithelium cell line) were run on 2-D GE
to investigate differentially expressed protein in tumor
compared to normal tissue. Approximately 580 spots
were detected in 2-D GE, as shown in Table 1, with an
average of 218 spots/gel.
Proteins of each sample were run on separate gels.
Figure 1 showed a representative image of gels for one
sample (A) and for the normal bile duct cell line (B),
while the images for the other samples run in different
gels are collected in Additional file 2.
The analysis indicated that 19 proteins, (one of them,
HBB, was identified by two peptides) were differentially
expressed within the two groups. In particular, 13 spots
were upregulated (> 2 fold) and 6 were downregulated
(< 0.5 fold) in ICC samples.
Mass Spectrometry was used to identify the selected
19 protein spots, which is reported in Table 2.
A consistent part of upregulated proteins (23.5%) in
ICC tissues, is related to redox biology. In particular
CAT, PRDX2, PRDX6 and SODM are highly expressed
compared to normal biliary epithelium cell line (10.6,
3.7, 3.7 and 3.5 fold, respectively). Other proteins with
an increased expression were related to metabolism
(Acyl-CoA-binding protein, Aminoacylase-1, Cyto-
chrome b-c1 complex subunit Rieske, mitochondrial),
cell structure (cytoplasmic Actin 2), signaling (Retinal
dehydrogenase 1), oxygen transport (Hemoglobin sub-
unit beta) and DNA binding (Histone H4). Downregu-
lated proteins (fold change between 0.45–0.18) are
involved in cell metabolism (Hydroxymethylglutaryl-
CoA synthase, mitochondrial Protein disulfide-isomerase
and Formimidoyltransferase-cyclodeaminase), cytoskel-
eton organization (Tubulin alpha-1B chain and Tropo-
myosin alpha-3 chain), and heat shock protein (Stress-70
protein, mitochondrial).
Immunohistochemistry validation of redox and
metabolism processes
In order to validate proteomic data, we selected four
among the up-regulated proteins found by previous ana-
lysis, all associated to overrepresented above mentioned
processes; we evaluated CAT (n = 15), SODM, PRDX6
and DBI/ACBP (n = 11 for the last three proteins) pro-
tein expression by IHC in an independent case series of
archival tissue samples derived from ICC Italian patients.
Table 3 summarized the score staining for each protein.
CAT was detected in all tumor tissue samples with dif-
ferent staining score: 2 out of 15 (13.3%) were weakly
Table 1 Number of spots detected for each sample and control
cells
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positive, 11 out of 15 (73.3%) were positive, and 2 out of
15 (13.3%) were strongly positive. SODM is overex-
pressed in all tumor tissues, 8 out of 11 tumors (73%)
are classified as 4+ and 3 out of 11 tumors (27%) as 3+.
PRDX6 is expressed in 8 out 11 samples (73%); of them,
5 are classified as 2+, 2 as 3+, one as 4+ and 3 were
negative. For these two proteins, the expression was
mainly weak or absent in the normal surrounding bile
duct. DBI/ACBP was expressed in all the samples with
different intensities, 2 with weak, 5 with intermediate,
and 4 strong intensities.
In all tested samples, the normal counterpart
expressed lower levels of the proteins examined. Fig-
ure 2 represents different score staining for CAT in
ICC samples, while representative IHC images of
tumor sections compared to the normal counterparts
for ACBP/DBI, PRDX6, and SODM are shown in
Additional file 3.
We exploited the Human Protein Atlas database to re-
trieve more information about protein expression. CCA
is included in the “liver cancer” disease, and for each
protein selected, a different number of CCA samples
were available. Six out of 8 expressed CAT, one with
strong intensity. SODM was highly expressed in 3 out of
4 CCA available, PRDX6 in 6 out of 7 CCAs (four with
strong-moderate expression), and for ACBP/DBI only
three samples were available, 2 of them with weak ex-
pression and one moderate. Additional file 4 summa-
rized data obtained for all the differentially expressed
proteins by using Protein Atlas database.
Fig. 1 Representative 2D gel images indicating the differential spots in normal cells (A) and ICC samples (B). Black circles indicate up-regulated
spots. Immobilized pH gradient 3–10 NL strips were used for the first dimension, 12.5% polyacrylamide gels were used for the second dimension
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Comparison between proteomic and transcriptomic data
In a previous work [22], we analyzed the gene expression
profiling of 13 ICC (including the five samples used for
proteomic analysis) fresh frozen tumors comparing them
with a dataset including normal bile ducts (GSE107102).
From this dataset, we extrapolated and reanalyzed data
of the five samples of interest to investigate if there was
a correspondence in terms of expression between
protein and transcriptomic data. As shown in Table 4,
considering protein expression as reference, and apply-
ing a logFC threshold of |0.5| for mRNA expression, we
have a protein-mRNA expression concordance of 50%, 5
out of 12 among up- and 4 out of 6 among down-
regulated targets in tumors compared to normal tissue.
We exploited GEPIA database to compare the expres-
sion of these targets between tumor and normal tissue at
Table 2 Up- and down-regulated proteins identified by proteomic analysis and MS in ICC compared to control
Acc. n° UniProtKB SPOT
ID














4079 Hemoglobin subunit beta Oxygen transport 14.9 89.8 18
sp|P68871|HBB_
HUMAN
4107 Hemoglobin subunit beta Oxygen transport 14.4 89.8 18
sp|P04040|CATA_
HUMAN








4383 Cytochrome b-c1 complex
subunit Rieske, mitochondrial
Metabolism 5.6 20.8 4
sp|P63261|ACTG_
HUMAN
4219 Actin, cytoplasmic 2 Cytoskeleton 4.8 29.1 5
sp|P30041|PRDX6_
HUMAN
4985 Peroxiredoxin-6 Redox homeostasis 3.7 64.7 10
sp|P32119|PRDX2_
HUMAN
4241 Peroxiredoxin-2 Redox homeostasis 3.7 36.4 8
sp|Q96IU4|ABHEB_
HUMAN





4373 Superoxide dismutase [Mn],
mitochondrial
Redox homeostasis 3.5 39.2 6
sp|P62805|H4_
HUMAN
4118 Histone H4 DNA binding 3.0 17.5 2
sp|P00352|AL1A1_
HUMAN






Metabolism 0.45 29.9 6
sp|P07237|PDIA1_
HUMAN





Metabolism 0.29 39.7 8
sp|P38646|GRP75_
HUMAN
5229 Stress-70 protein, mitochondrial Heat shock response 0.23 15.5 7
sp|P68363|TBA1B_
HUMAN
4835 Tubulin alpha-1B chain Cytoskeleton 0.22 26.8 7
sp|P06753|TPM3_
HUMAN
4302 Tropomyosin alpha-3 chain Cytoskeleton 0.18 27.4 5
Fold change represents the ratio between the mean percentage relative volume (%V) (%V = V(single spot)/V(total spot)) determined in ICC and the normal
sample. Score refers to the sum of the Mascot ion scores of all of the peptides that were identified for a given protein. Sequence coverage is the % of
aminoacidic sequences identified by MS. Number of Unique Peptides is the number of peptides matching the identified proteins
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mRNA levels; 36 ICC and 9 normal tissues are included
in the analysis (TCGA dataset). Boxplot for each targets
were summarized in Additional file 5 and the concord-
ance between TCGA data and our GEP analysis and
TCGA data and proteomic analysis was reported. Results
are only partially comparable, mainly due to the small
number of samples analyzed in each case series. No as-
sociation between targets expression and survival was
found using TCGA dataset (Additional file 6), with the
exception of PRDX2, whose high expression in
Table 3 Score of catalase immunostaining on ICC and normal counterpart tissues
Sample CAT SODM DBI PRDX6




Normal area Tumor area Normal area Tumor
area
Normal area
1 positive negative NA NA NA NA NA NA
2 weakly positive negative NA NA NA NA NA NA
3 positive negative NA NA NA NA NA NA
4 weakly positive negative NA NA NA NA NA NA
5 positive negative 4+ Weak positivity Strong positivity Intermediate
positivity
negative negative
6 positive negative 4+ Weak positivity Intermediate
positivity
Weak positivity 2+ negative
7 positive negative 3+ Weak positivity Intermediate
positivity
Weak positivity 2+ negative
8 strongly
positive
negative NA NA NA NA NA NA








Weak positivity 2+ negative
11 positive negative 4+ negative Weak positivity Weak positivity 4+ Weak
positivity
12 positive negative 4+ negative Weak positivity Weak positivity negative negative
13 strongly
positive
negative 3+ Weak positivity Intermediate
positivity
Weak positivity 2+ negative











16 NA NA 4+ Weak positivity Strong positivity Weak positivity 2+ negative
NA not available
Fig. 2 Representative CAT immunostaining images of ICC tissues. A-C-E-G showed ICC tissues with different CAT staining (A: weakly positive; C:
positive; E-G: highly positive). B-D-F-H showed the corresponding normal surrounding tissues. Images were acquired at 40X
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associated with poor disease free survival (p = 0.01) and
of ALDH1A1, whose low expression is associated with
poor disease free survival (p = 0.03).
Discussion
In the last decade, the identification of putative targets
for CCA treatment has become challenging. To date,
mutational and transcriptomic profiles, as well as methy-
lation status and fusions assessment, are deeply investi-
gated and many progresses in terms of classification and
identification of prognostic biomarkers have been made.
It is well-known that all the above-mentioned alterations
are strictly associated to ethnicity and etiology and we
assume the same behavior for proteomic profile. This,
together with the increasing incidence of ICC in Italy
and the lack of effective therapies prompted us to
analyze the protein expression profile of a small cohort
of ICC derived from Italian patients. The first limit of
this study is the small number of patients available, but
it can be considered a training analysis, which suggests
potential targets suitable for therapies to be tested in a
validation set. Nevertheless, this study pointed out the
impairment of the antioxidant system, with a subsequent
accumulation of free radicals. In particular, the main
process in which the deregulated proteins are involved is
the redox pathway.
It is well established that metabolic processes play a
key role in tumor progression. Here, we evidenced an
up-regulation of ACBP1, confirmed also in the inde-
pendent case series by IHC, which is already
described in other tumor types, especially in glioblast-
oma and astrocytoma [23, 24]. In physiological condi-
tions, its role is the maintenance of lipid metabolism,
steroidogenesis, and peptide hormone release; when
overexpressed, it supports tumor growth by control-
ling the availability of long chain fatty acids which
are processed by mitochondria with a fatty oxidation
reaction [25]. ACBP1/DBI silencing induces cell sen-
escence, reduces cell proliferation, delays tumor initi-
ation and prolongs survival in in vivo model.
Moreover, due to its role as adaptor to microenviron-
ment changes, it seems to promote the cancer stem
cell niche during neurogenesis [26].
HBB is involved in oxygen metabolism. High ex-
pression was detected in breast cancer, in particular
in bone metastasis [27]. Authors suggested a positive
correlation between HBB expression and ability of
disseminating tumor cells in other organs, indicating
a more aggressive phenotype [28]. This data is also
confirmed by the work of Zheng and coll. in which
HBB is abundantly expressed in circulating tumor
cells of breast and prostate cancer patients and its ex-
pression is closely detected in circulating tumor cells
(CTC), and not in primary tumors [29]. CAT and
SODM, both involved in antioxidant processes, are
up-regulated in our cohort of ICC patients. Loilome
and collaborators demonstrated, in an O. viverrini
hamster cholangiocarcinoma model, that both en-
zymes are highly expressed during cholangiocarcino-
genesis, while there is a decreased expression when
Table 4 Comparison of protein and mRNA expression in ICC samples
Protein ID Protein Name Expression in ICC vs normal Gene Name Log2FC in ICC vs normal
P07108 ACBP UP DBI 0.530
P68871 HBB UP HBB −0.343
P04040 CATA UP CAT −2-284
Q03154 ACY1 UP ACY1 −0.22
P47985 UCRI UP UQCRFS1 0.094
P63261 ACTG UP ACTG −1.213
P30041 PRDX6 UP PRDX6 − 0993
P32119 PRDX2 UP PRDX2 0.747
Q96IU4 ABHEB UP CIB1 1.103
P04179 SODM UP SOD2 1.968
P62805 H4 UP HIST1H4A 2.571
P00352 ALIA1 UP ALDH1A1 −3.260
P54868 HMCS2 DOWN HMGCS2 − 1809
P07237 PDIA1 DOWN P4HB 0.018
O95954 FTCD DOWN FTCD −3.798
P38646 GRP75 DOWN HSPA9 −2.673
P68363 TBA1B DOWN TUBA1B −0.939
P06753 TPM3 DOWN TPM3 0.936
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tumors are well established [30]. The same group
demonstrated that both proteins are expressed at dif-
ferent levels in CCA tissues, but they are also
expressed in normal bile ducts and hepatocytes [31].
Interestingly, its activity is dramatically reduced in
CCA compared to normal bile ducts. In contrast, high
expression and activity of antioxidant enzymes, among
them SODM and CAT, are found in a cholangiocytes
hydrogen peroxide resistant cell line obtained by
gradual and continuous exposition to hydrogen perox-
ides. This cell line had a higher proliferation rate and
a more aggressive phenotype compared to the paren-
tal one; thus, it may be a suitable model of cholangio-
carcinogenesis [32]. In our validation case series, we
found that CAT protein is expressed at different
levels in cancer tissues, but not in normal adjacent
ones. A recent work demonstrated that the presence
of variants in genes associated to oxidative stress
pathway may affect the response to chemotherapy.
Moreover, CAT overexpression inhibits proliferation
in vitro of CCA in vitro models and promotes cis-
platin and doxorubicin-induced antitumor activity,
while low levels of CAT induce resistance to these
chemotherapeutic agents [33]. We analyzed the ex-
pression of another protein strictly associated with
CAT, SODM, found overexpressed by proteomic data.
The same trend was revealed in the independent case
series tested by IHC.
ACY1 is found up-regulated in different tumor types.
Literature data demonstrated that ACY1 knockdown in
colorectal cancer cells inhibits proliferation and in-
creases apoptosis, becoming an interesting target to ex-
plore [34]. In contrast, ACY1 is a putative tumor
suppressor in small cell lung cancer and hepatocarci-
noma [35, 36].
The impairment of UQCRFS1, involved in mito-
chondrial stability, electron transport driving oxidative
phosphorylation, expression was described in gastric
cancers where it is frequently amplified and associ-
ated to tumor progression [37]. Opposite results are
shown in clear cell renal carcinoma; UQCRFS1 is
downregulated, probably due to a DNA hypermethyla-
tion of that region [38]. ACTB expression is high in
tumor tissues and cell lines; its deregulation in tu-
mors is associated to loss of polarization and major
invasiveness and metastatic potential [39], also de-
scribed in metastatic breast cancer [40]. PRDX2 is
already described as overexpressed in CCA tissues
compared to the normal surrounding ones [40], while
PRDX6 is overexpressed in the inflammation process
induced by Clonorchis Siniensis [41]. The up-
regulation of both PRDX2 and PRDX6 is described in
many tumors and correlated with invasiveness, migra-
tion, drug resistance and enhancing stem cell
properties, in particular in NSCLC, colorectal cancer,
and esophageal carcinoma [42–45]. From IHC ana-
lysis, we found that about 73% of ICC expressed
higher levels of PRDX6 compared to the normal adja-
cent tissues, in line with published data. PRDX6 over-
expression is also associated with poor prognosis and
overall survival in ovarian cancer [46]. HIST1H4A re-
sulted highly up-regulated in exosomes released by
NSCLC [47]. A recent study conducted on CCA pa-
tients showed that high expression of ALDH1A1 cor-
related with a more favorable prognosis [48]; in many
studies, ALDH1A1 is a cancer stem cell marker and a
suitable target for therapy and only its activity is as-
sociated to worse prognosis [49, 50].
Another limit of this study is the use of normal im-
mortalized colangiocytes cell line as control in MS ex-
periments, instead of the most appropriate normal
biliary tissue; in fact, the cell line lacks the microenvir-
onment, the cellular components usually present in
tumor surrounding tissues, actually weakening and po-
tentially impairing our findings. However, the proteins
identified in our study were validated in an independent
cohort of ICC tissues comparing their expression with
the normal surrounding tissues, albeit on a limited num-
ber of cases.
Globally, this study, even if conducted on a small
number of samples, provided precious information
about the role of oxidative and metabolic processes in
CCA progression, suggesting also that they may be
good targets for therapy in CCA. Combining therapies
able to tip the balance towards the anti-cancer activ-
ity of these pathways with standard chemotherapy
could be an alternative approach in CCA treatment.
Recently, it was demonstrated that the administration
of metformin in association to Cisplatin enhances the
oxidative stress mediated cell death pathway, hence
increasing the efficacy of Cisplatin alone [50]. More-
over, these pathways may have a potential as prognos-
tic biomarkers in serum. Uchida and collaborators
demonstrated that an increase concentration of react-
ive oxygen metabolites and a decrease level of anti-
oxidative metabolites in serum are associated to poor
outcome in CCA patients, suggesting the importance
of such processes in tumor progression [51]. The
complexity of metabolic and oxidative pathways de-
serves tailored studies to clarify their role in cancer
development, progression and drug resistance.
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